Glutaredoxin-1 (GLRX1)

Glutaredoxin-1 (GLRX1) is a small redox enzyme of the thioredoxin superfamily, functioning primarily as a glutathione-dependent oxidoreductase and thioltransferase. It selectively catalyzes the reduction (removal) of glutathione (GSH) from protein thiols (deglutathionylation), thereby maintaining the reduced state of cellular proteins and contributing to antioxidant defense, redox signaling, and post-translational regulation of protein function. GLRX1 has a crucial role in controlling cellular redox homeostasis and modulating key signaling and metabolic pathways, including the regulation of lipid metabolism in the liver, vascularization, inflammatory responses, and apoptosis. GLRX1 is cytoplasmic, redox-sensitive, and operates in concert with glutathione and glutathione reductase. Dysregulation or decreased activity of GLRX1 is implicated in various pathologies, including cardiovascular disease, inflammation, metabolic diseases (fatty liver, obesity), and cancer. While not currently a direct pharmacological target of approved drugs, GLRX1 is considered a promising therapeutic target for a range of redox-associated disorders, with the S-glutathionylation status of proteins serving as a potential biomarker of its functional state[1][2][3][5].

Other names

ThioltransferaseGRX1GLRX

Enzymatic reduction of protein S-glutathionylation (deglutathionylation), Redox regulation of target proteins, Modulation of protein and cellular activity through redox-dependent modifications